Hetero Labs Limited — Velpatasvir Exporter Profile
Indian Pharmaceutical Exporter · #2 for Velpatasvir · $3.7M export value · DGFT Verified
Hetero Labs Limited is the #2 Indian exporter of Velpatasvir with $3.7M in export value and 74 verified shipments. Hetero Labs Limited holds a 15.0% market share in Velpatasvir exports across 17 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.
Hetero Labs Limited — Velpatasvir Export Profile: Buyers & Destinations
Where Does Hetero Labs Limited Export Velpatasvir?
| Country | Value | Shipments | Share |
|---|---|---|---|
| KAZAKISTAN | $481.4K | 11 | 18.9% |
| UZBEKISTAN | $400.0K | 8 | 15.7% |
| KYRGHYSTAN | $253.3K | 6 | 10.0% |
| MYANMAR | $205.0K | 7 | 8.1% |
| MOLDOVA,REPUBLIC OF | $200.8K | 6 | 7.9% |
| THAILAND | $161.5K | 5 | 6.3% |
| AZARBAIJAN | $137.2K | 5 | 5.4% |
| MAURITIUS | $100.0K | 2 | 3.9% |
| BURUNDI | $77.6K | 3 | 3.1% |
| ARMENIA | $71.6K | 3 | 2.8% |
Hetero Labs Limited exports Velpatasvir to 20 countries. The largest destination is KAZAKISTAN accounting for 18.9% of Hetero Labs Limited's Velpatasvir shipments, followed by UZBEKISTAN (15.7%) and KYRGHYSTAN (10.0%). These destinations reflect Hetero Labs Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Velpatasvir from Hetero Labs Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER OF | MYANMAR | $2.0M | 56 |
| TO THE ORDER OF , | KAZAKISTAN | $118.8K | 3 |
| TO THE ORDER | NIGERIA | $71.3K | 4 |
| M/S | KAZAKISTAN | $50.0K | 1 |
| ALCHEM INDUSTRIES SPRL | BURUNDI | $45.0K | 2 |
| M/S........ | CAMBODIA | $42.4K | 1 |
| TO THE ORDER OF, | KAZAKISTAN | $39.3K | 1 |
| TO THE ORDER OF | ARMENIA | $20.0K | 2 |
Hetero Labs Limited supplies Velpatasvir to 8 buyers globally. The largest buyer is TO THE ORDER OF (MYANMAR), followed by TO THE ORDER OF , (KAZAKISTAN) and TO THE ORDER (NIGERIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Velpatasvir Export Value and How Much Does Hetero Labs Limited Contribute?
India exported $8.8M worth of Velpatasvir through 671 shipments from 103 suppliers to 95 countries, serving 235 buyers globally. Hetero Labs Limited contributes $3.7M to this total, accounting for 15.0% of India's Velpatasvir exports. Hetero Labs Limited ships Velpatasvir to 20 countries through 8 buyers.
What Is the Average Shipment Value for Hetero Labs Limited's Velpatasvir Exports?
Hetero Labs Limited's average Velpatasvir shipment value is $50.0K per consignment, based on 74 shipments totaling $3.7M. The largest destination is KAZAKISTAN (18.9% of Hetero Labs Limited's Velpatasvir exports).
How Does Hetero Labs Limited Compare to Other Indian Velpatasvir Exporters?
Hetero Labs Limited ranks #2 among 103 Indian Velpatasvir exporters with a 15.0% market share. The top 3 exporters are HETERO LABS LIMITED ($3.7M), MYLAN LABORATORIES LIMITED ($3.1M), NATCO PHARMA LIMITED ($550.0K). Hetero Labs Limited processed 74 shipments to 17 destination countries.
What Velpatasvir Formulations Does Hetero Labs Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| VELSOF, SOFOSBUVIR 400 MG + VELPATASVIR | $655.6K | 14 |
| VELSOF SOFOSBUVIR 400 MG + VELPATASVIR 1 | $424.2K | 9 |
| VELSOF SOFOSBUVIR+VELPATASVIR TABLET 28S(236,600 TABLET) PACK OF 28 'S | $150.0K | 3 |
| VELSOF SOFOSBUVIR+VELPATASVIR TABLET 28S(28,000 TABLET) PACK OF 28 STBS | $103.3K | 3 |
| VELSOF (SOFOSBUVIR 400 MG + VELPATASVIR | $99.4K | 3 |
| VELSOF SOFOSBUVIR+VELPATASVIR TABLET 28S | $92.2K | 4 |
| HEPVEL SOFOSBUVIR+VELPATASVIR TABLET 28S(48048 TABLET) PACK OF 28 'STBS | $61.5K | 3 |
| VELSOF SOFOSBUVIR 400 MG VELPATASVIR 100 MG TABLETS TABS PACK SIZE28 s TAXINV SI0222253420 DT 11 03 2023 | $52.8K | 2 |
| VELSOFSOFOSBUVIR+VELPATASVIR TABLET 28SBATCH NOS: FGV240101(1,350 CON) | $52.2K | 3 |
| HEPVEL SOFOSBUVIR 400 MG + VELPATASVIR 1 | $50.0K | 1 |
Hetero Labs Limited exports 35 distinct Velpatasvir formulations including tablets, capsules, syrups, and combination drugs. The top formulation is VELSOF, SOFOSBUVIR 400 MG + VELPATASVIR with 14 shipments worth $655.6K.
How Does Hetero Labs Limited Compare to Nearest Velpatasvir Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | HETERO LABS LIMITED ★ | $3.7M | 74 | 17 | $50.0K |
| 1 | MYLAN LABORATORIES LIMITED | $3.1M | 63 | 23 | $50.0K |
| 4 | NATCO PHARMA LIMITED | $550.0K | 11 | 5 | $50.0K |
Hetero Labs Limited ranks #2 among 103 Indian Velpatasvir exporters. Average shipment value of $50.0K compared to the market average of $85.6K. The closest competitors by value are MYLAN LABORATORIES LIMITED and NATCO PHARMA LIMITED.
Which Indian Ports Ship Velpatasvir Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 151 | 22.5% |
| SAHAR AIR | 140 | 20.9% |
| DELHI AIR CARGO ACC (INDEL4) | 71 | 10.6% |
| Bombay Air | 62 | 9.2% |
| DELHI AIR | 50 | 7.5% |
| AHEMDABAD AIR ACC (INAMD4) | 37 | 5.5% |
| AHEMDABAD AIR | 33 | 4.9% |
| Ahmedabad Air | 21 | 3.1% |
What Other Antiviral & HIV Medications Products Does Hetero Labs Limited Export?
Hetero Labs Limited also exports these antiviral & hiv medications products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Hetero Labs Limited's Velpatasvir Exports
The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.
Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.
The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.
Hetero Labs Limited — Regulatory Compliance & Quality Standards
Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.
About Hetero Labs Limited
Hetero Labs Limited exports 46 products worth $319.3M. Beyond Velpatasvir, top products include Tenofovir, Dolutegravir, Ritonavir, Acyclovir, Valacyclovir. View the complete Hetero Labs Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Velpatasvir — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Velpatasvir shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 74 individual customs records matching Hetero Labs Limited exporting Velpatasvir, covering 35 formulations to 20 countries via 8 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 95+ countries, 235+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Velpatasvir Export Data from Hetero Labs Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Hetero Labs Limited's Velpatasvir exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Hetero Labs Limited
Full Company Profile →
46 products · $319.3M total trade · 18 categories
Velpatasvir Stats
Company Overview
Top Products by Hetero Labs Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Hetero Labs Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Velpatasvir. For current shipment-level data, contact TransData Nexus.